

RESEARCH PAPER

Prostanoid EP₁ receptors mediate up-regulation of the orphan nuclear receptor Nurr1 by cAMP-independent activation of protein kinase A, CREB and NF-κB

R Ji¹, CM Sanchez¹, CL Chou¹, XB Chen¹, DF Woodward² and JW Regan¹

¹Department of Pharmacology & Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, USA, and ²Department of Biological Sciences, Allergan, Inc. Irvine, CA, USA

Correspondence

John W Regan, Department of Pharmacology & Toxicology, College of Pharmacy/The University of Arizona, 1703 E. Mabel St., Tucson, AZ 85721-0207, USA. E-mail: regan@pharmacy.arizona.edu

Keywords

EP₁ prostanoid receptor; G-protein coupled receptors; Nurr1; NR4A2; orphan nuclear receptors; prostaglandin E₂; PGE₂; PKA; CREB; NF-κB

Received

3 June 2011

Revised

6 November 2011

Accepted

4 December 2011

BACKGROUND AND PURPOSE

Prostaglandin E₂ (PGE₂) stimulation of the G protein-coupled prostanoid EP₁ receptor was found to up-regulate the expression of Nur-related factor 1 (Nurr1) (NR4A2), a transcription factor in the NR4A subfamily of nuclear receptors. The present studies characterize the molecular mechanism of this up-regulation.

EXPERIMENTAL APPROACH

The expression of Nurr1 was examined by immunoblot analysis, the polymerase chain reaction and reporter gene assays in human embryonic kidney (HEK) cells stably expressing the recombinant EP₁ receptor and in SH-SY5Y neuroblastoma cells expressing endogenous EP₁ receptors. Signalling pathway inhibitors were used to examine the roles of Rho, PKA, the cAMP response element binding protein (CREB) and NF-κB on the PGE₂ stimulated up-regulation of Nurr1. CREB and NF-κB signalling were also examined by immunoblot analysis and reporter gene assays.

KEY RESULTS

The EP₁ receptor mediated up-regulation of Nurr1 was blocked with inhibitors of Rho, PKA, NF-κB and CREB; but PGE₂ failed to significantly stimulate intracellular cAMP formation. PGE₂ stimulation of the EP₁ receptor induced the phosphorylation and activation of CREB and NF-κB, which could be blocked by inhibition of PKA.

CONCLUSIONS AND IMPLICATIONS

PGE₂ stimulation of the human EP₁ receptor up-regulates the expression of Nurr1 by a mechanism involving the sequential activation of the Rho, PKA, CREB and NF-κB signalling pathways. EP₁ receptors are implicated in tumorigenesis and the up-regulation of Nurr1 may underlie the anti-apoptotic effects of PGE₂.

Abbreviations

CREB, cAMP response element binding protein; EP, E-type prostanoid receptor; Nurr1, Nur-related factor 1 or NR4A2; PKAc, the catalytic subunit of PKA

Introduction

Prostaglandin E₂ (PGE₂) is one of the major products of the COX pathway that exerts its actions through the activation of four different E-type prostaglandin receptors (EP). These

receptors are members of the G protein-coupled family of receptors and are designated EP₁, EP₂, EP₃ and EP₄, (receptor nomenclature follows Alexander *et al.*, 2011) and are the products of four separate genes that have evolved to subserve the activation of unique signal transduction pathways

leading to the regulation of different physiological responses (Coleman *et al.*, 1994; Regan, 2003; Sugimoto and Narumiya, 2007). Classically, these receptors were distinguished by their differential coupling to G proteins and their effects on smooth muscle. Thus, EP₁ receptors were generally acknowledged to couple to G_q resulting in the activation of Ca²⁺ signalling and the contraction of smooth muscle. The EP₂ and EP₄ receptors, on the other hand, were associated with coupling to G_s, resulting in the stimulation of intracellular cAMP formation and smooth muscle relaxation. EP₃ receptors were initially recognized for coupling to G_i, resulting in the inhibition of intracellular cAMP formation and smooth muscle contraction.

It is now appreciated that the EP receptor subtypes can couple to multiple G proteins leading to the activation of diverse, but nevertheless unique, signalling networks. For example, the EP₃ receptors were found to undergo extensive alternative mRNA splicing resulting in isoforms that could differentially couple to G_i and G_s and G_q (Kotani *et al.*, 1997). Although EP₂ receptors to date have only been shown to couple to G_s, they can also activate β -catenin dependent Tcf/Lef signalling in addition to activating a traditional cAMP/protein kinase A (PKA) pathway (Fujino *et al.*, 2002). EP₄ receptors can activate β -catenin-dependent Tcf/Lef signalling as well (Fujino *et al.*, 2002), but in contrast to the EP₂ receptors, the EP₄ receptors do this through coupling to G_i and the activation of a PI3K signalling pathway (Fujino and Regan, 2006).

We have recently found that EP₁ receptors can couple to G_i in addition to coupling to G_q (Ji *et al.*, 2010). Coupling of the EP₁ receptor to G_i results in the activation of a PI3K, Akt and mTOR signalling cascade leading to the up-regulation of hypoxia-inducible factor-1 α (HIF-1 α). This up-regulation of HIF-1 α occurred under normoxic conditions and involved increased translation rather than increased transcription. We further showed that the EP₁ receptor-mediated up-regulation of HIF-1 α in HepG2 hepatocellular carcinoma cells was associated with the up-regulation of mRNA-encoding lymphatic vascular endothelial growth factor-C (VEGF-C). These and other findings (Huang *et al.*, 2005; Han *et al.*, 2006) strongly suggest that the EP₁ receptor-mediated up-regulation of HIF-1 α and VEGF-C could be driving tumour angiogenesis and metastasis in hepatocellular carcinoma.

EP₁ receptors have also been implicated in the development and/or progression of colon, lung, breast and skin cancer (Chell *et al.*, 2006; Fulton *et al.*, 2006). Interestingly, while the role of EP₁ receptors in various epithelial cell cancers suggest anti-apoptotic effects and the promotion of cell survival, in the central nervous system (CNS), the activation of EP₁ receptors by PGE₂ can induce apoptosis and mediate neurotoxicity. For example, genetic ablation or pharmacological blockade of the EP₁ receptor in mice dramatically decreased excitotoxic and ischemia-induced brain injury (Ahmad *et al.*, 2006; Kawano *et al.*, 2006). Similarly, in rabbits, pharmacological blockade of the EP₁ receptor significantly decreased the extent of brain damage caused by intraventricular haemorrhage and was associated with decreased apoptosis and neuronal degeneration (Vinukonda *et al.*, 2010). In primary cultures of rat mesencephalic neurons, stimulation of the EP₁ receptor selectively killed dopaminergic neurons and pharmacological blockade of

the EP₁ receptor protected dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity (Carrasco *et al.*, 2007). Although inhibition of the Na⁺-Ca²⁺ exchanger has been implicated in the excitotoxic brain injury caused by EP₁ receptor activation (Kawano *et al.*, 2006), the molecular mechanisms that could potentially explain EP₁ receptor-mediated neuronal degeneration and apoptosis are unknown.

Recently, using DNA microarray analysis, we discovered that PGE₂ treatment of HEK cells stably expressing the recombinant human EP₁ receptor resulted in a strong up-regulation of Nurr1 (XB Chen and JW Regan, unpublished). Nurr1, also known as NR4A2, is a transcription factor in the NR4A subfamily of nuclear receptors, which includes two additional members, Nur77 and Nor-1 (Pearen and Muscat, 2010). These so-called orphan receptors are interesting because they activate gene expression in a constitutive ligand-independent manner, and thus, are essentially proxies for those factors that can up-regulate their expression. In the present case, the up-regulation of Nurr1 and activation of Nurr1-dependent transcriptional activity is controlled by PGE₂ signalling through the EP₁ receptor. The NR4A receptor subfamily function as immediate early response genes and have a wide variety of physiological and pathophysiological actions (Zhao and Bruemmer, 2010). Nurr1 itself is essential for the development and maintenance of midbrain dopaminergic neurons and has anti-apoptotic actions in colon (Holla *et al.*, 2006), cervical (Ke *et al.*, 2004) and squamous cell carcinomas (Shigeishi *et al.*, 2011).

The purpose of this study was to understand the signalling mechanisms responsible for the up-regulation of Nurr1 by the human EP₁ prostanoid receptor. We have found that PGE₂ stimulation of the EP₁ receptor up-regulates the expression of Nurr1 by a cAMP-independent activation of PKA, cAMP response element binding protein (CREB) and nuclear factor-kappa B (NF- κ B). Additionally, this up-regulation of Nurr1 involves the activation of Rho signalling, which is likely to occur through the coupling of the EP₁ receptor to G_{12/13}. These findings provide new knowledge concerning the functional regulation of Nurr1 by PGE₂ and have implications for understanding the role of prostanoid EP₁ receptors in cancer and neuronal cell death.

Methods

Cell culture

HEK cells stably expressing the recombinant human EP₁ prostanoid receptor (HEK-EP1) or expressing the empty vector (HEK-pCEP4) were prepared as previously described (Ji *et al.*, 2010). The cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 250 μ g·mL⁻¹ geneticin, 100 μ g·mL⁻¹ gentamicin and 200 μ g·mL⁻¹ hygromycin B. A human neuroblastoma cell line (SH-SY5Y) was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in Eagle's minimal essential medium/F12 containing 10% FBS. The cells were cultured in a humidified incubator at 37°C in 5% CO₂/95% air.

Immunoblotting

The cells were plated at a density of 10⁶ cells per well in six-well plates and incubated overnight at 37°C. The cells

were then incubated with PGE₂ as described in the figure legends, and immunoblotting was performed as previously described (Ji *et al.*, 2010). Briefly, whole cell lysates were prepared and ~50 µg of protein was analysed by electrophoresis on 10% SDS-PAGE gels and transferred to PVDF membranes. Following an overnight incubation at 4°C with the primary antibodies, the membranes were incubated for 1 h at room temperature with the secondary antibodies. Antibodies against phospho-CREB/phospho-ATF-1, phospho-I-κB, phospho-NF-κB and Nurr1 were used at a final dilution of 1:1000 in 3% non-fat milk. Horseradish peroxidase-conjugated secondary antibodies were used at a final dilution of 1:10 000 in 3% non-fat milk. Following incubation with the secondary antibodies, the membranes were washed and immunoreactivity was detected by enhanced chemiluminescence. To ensure equal loading of proteins, the membranes were stripped and re-probed with antibodies to either vinculin or ERK 1/2.

Luciferase reporter gene assay

Cells were split into six-well plates and grown to ~75% confluence. Approximately 24 h later, the cells were co-transfected with 2 µg/well of a firefly luciferase reporter plasmid (pGL3/HRE-Luc27) under the control of a Nurr1 binding response element (NBRE) or a cAMP response element (CRE) or a NF-κB response element and 10 ng per well of the *Renilla* luciferase reporter, pRL-CMV, using 5 µL FuGENE-HD. Approximately 18 h later, the cells were treated with either vehicle (0.1% dimethyl sulfoxide in phosphate-buffered saline solution) or 1 µM PGE₂. The next day, cell lysates were prepared and 2 µL were used to measure luciferase activity using the Dual Luciferase Reporter Assay System according to the manufacturer's instructions. The data were normalized by calculating ratios of firefly luciferase scores to the corresponding *Renilla* luciferase values.

Quantitative real-time PCR (qPCR)

qPCR was performed as previously described (Ji *et al.*, 2010) using TaqMan Gene Expression Assay primers for Nurr1 (assay ID no. Hs00428691_m1) from Applied Biosystems (Foster City, CA, USA). PCR reactions were composed of 40 cycles of 95°C for 15 s and 60°C for 45 s in an ABI 7500 thermal cycler (Applied Biosystems, Foster City, CA, USA). Threshold values (Ct) were determined automatically by the system software and relative mRNA expression was analysed by the comparative ΔΔCt method. Data were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

cAMP assay

The cells were cultured in six-well plates as above, and 16 h before the assay, the regular culture medium was replaced with Opti-MEM containing 250 µg·mL⁻¹ geneticin and 100 µg·mL⁻¹ gentamicin. Following a 15 min pretreatment with 3-isobutyl-1-methylxanthine (IBMX; 0.1 mg·mL⁻¹), the cells were incubated with either vehicle (0.1% dimethyl sulfoxide) or 1 µM PGE₂ for 10 min at 37°C. The media were removed and the cells were placed on ice in preparation for the cAMP assay, which was performed as previously described (Fujino and Regan, 2006).

Data analysis

Unless otherwise stated, data are expressed as the means ± S.E.M. Differences between means were analysed by one-way ANOVA, followed by Bonferroni post test using GraphPad Prism version 4.00 for Windows (San Diego, CA). P values less than 0.05 were taken as showing significant differences between means.

Materials

Trizol® Reagent, Dulbecco's modified Eagle's medium (DMEM), Eagle's minimum essential medium/F12 (MEM/F12), Opti-MEM, hygromycin B, geneticin and gentamicin were from Invitrogen (Carlsbad, CA, USA). Absolutely RNA Miniprep kit was from Strategene (La Jolla, CA, USA). Antibodies against Nurr1, phospho-IκBα protein (Ser32/36; product no. sc-101713) were from Santa Cruz (San Jose, CA, USA). Anti-mouse IgG conjugated with horseradish peroxidase, vinculin antibodies, IBMX and PKA were from Sigma-Aldrich (St Louis, MO, USA). iScript cDNA kit, PVDF membranes and Transfectin reagent were from Bio-Rad Laboratories (Hercules, CA, USA). Cell lysis buffer and antibodies against phospho-CREB/phospho-activating transcription factor-1 (ATF-1) (Ser¹³³; product no. 9191), phospho-PKA (Thr¹⁹⁷; product no. 4781), phospho-NF-κB p65 (Ser²⁷⁶; product no. 3037) were from Cell Signaling Technology (Waltham, MA, USA). PGE₂ was from Cayman Chemical Company (Ann Arbor, MI, USA). 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester (BAPTA/AM), bisindolylmaleimide I (BIM), H89, protein kinase A inhibitor (PKI) and C3 toxin were from Calbiochem (San Diego, CA, USA). FuGENE 6 was from Roche (San Francisco, CA, USA). The Dual Luciferase Reporter Assay System and the *Renilla* luciferase reporter (pRL-CMV) were from Promega (Madison, WI, USA). [³H]cAMP was from PerkinElmer Life & Analytical Sciences (Boston, MA, USA).

Results

Up-regulation of Nurr1 mRNA and protein expression by PGE₂ in HEK cells stably expressing the human EP₁ receptor

Using DNA microarray analysis, we had previously found that mRNA encoding the orphan nuclear receptor Nurr1 (NR4A2) was strongly up-regulated by PGE₂ stimulation of HEK cells stably expressing the recombinant human EP₁ receptor (XB Chen and JW Regan, unpublished observations). qPCR analysis and immunoblotting were therefore used to examine the time course and concentration response of Nurr1 expression following the treatment of HEK-EP1 cells with PGE₂. As shown in Figure 1A, there was a strong induction of Nurr1 mRNA expression within 1 h of treatment with 1 µM PGE₂, which decreased but was still elevated over pretreatment levels after 6 h. Figure 1B shows that Nurr1 protein expression was strongly induced after 3 and 6 h of treatment with 1 µM PGE₂ and that it was less but still clearly elevated over pretreatment levels after 12 h. Figure 1C shows the concentration-dependent response of the up-regulation of Nurr1 protein expression following treatment of HEK-EP1 cells with either vehicle or 10⁻⁹–10⁻⁵ M PGE₂ for 3 h. As




Figure 1

Time course for the PGE₂-stimulated up-regulation of Nurr1 mRNA (A) and concentration-response (B) and time course for the protein expression (C) of Nurr1 in HEK cells stably expressing the human EP₁ receptor. (A) HEK-EP1 cells were incubated with 1 μ M PGE₂ at 37°C for the indicated times and then RNA was isolated and used for quantitative real-time PCR with primers specific for either Nurr1 or GAPDH. Data were analysed by the comparative $\Delta\Delta$ Ct method, relative to the expression of GAPDH. Data are the means $\pm$ SEM ($n = 4$) of the pooled data from two independent experiments each done in duplicate. *** $P < 0.001$; compared with time 0; one-way ANOVA, followed by Bonferroni post-test. (B) HEK-EP1 cells were incubated with 1 μ M PGE₂ at 37°C for the indicated times and were subjected to immunoblot analysis using antibodies against human Nurr1 or ERK 1/2 as described in the methods section. (C) HEK-EP1 cells were incubated with either vehicle (veh) or the indicated concentrations of PGE₂ for 3 h at 37°C and were subjected to immunoblot analysis using antibodies against human Nurr1 or vinculin. Immunoblots are representative from one of three independent experiments.

compared with treatment with vehicle, there was already a significant up-regulation of Nurr1 expression at 10⁻⁹ M PGE₂. Indeed, treatment with 10⁻⁹ M PGE₂ induced roughly half the maximal expression of Nurr1 observed at 10⁻⁵ M PGE₂, which compares favourably to the binding of PGE₂ to HEK-EP1 cells (IC₅₀ = 3.6 nM) or to the stimulation of inositol phosphates

formation by PGE₂ in these cells (EC₅₀ = 4.8 nM; Ji *et al.*, 2010). These findings indicate that PGE₂ stimulation of the human EP₁ receptor involves an initial increase in Nurr1 gene transcription followed by increased translation and up-regulation of Nurr1 protein expression.

The up-regulation of Nurr1 mediated by the EP₁ receptor involves the activation of NF- κ B and CREB

It has been previously reported that in synovial tissue from patients with rheumatoid arthritis, pro-inflammatory mediators can up-regulate the expression of Nurr1 by increased transcription involving interactions of NF- κ B and CREB with the proximal promoter of the Nurr1 gene (McEvoy *et al.*, 2002). The family of NF- κ B proteins are transcription factors that bind to NF- κ B response elements in target genes (Hayden and Ghosh, 2008; Vallabhapurapu and Karin, 2009). The binding of inhibitory subunits, referred to as I- κ B, regulates NF- κ B activity. In the classical pathway of activation, the phosphorylation of I- κ B leads to the dissociation of the NF- κ B/I- κ B complex and translocation of NF- κ B to the nucleus. We therefore examined the activation of NF- κ B-mediated transcriptional activity and the phosphorylation of I- κ B following the treatment of HEK-EP1 cells with PGE₂. As shown in Figure 2A, treatment of HEK-EP1 cells with 1 μ M PGE₂ strongly stimulated NF- κ B responsive luciferase reporter gene activity but had no effect in control HEK cells stably transfected with empty vector (HEK-pCEP4). In Figure 2B, immunoblot analysis was used to examine the phosphorylation of I- κ B following treatment of HEK-EP1 cells with 1 μ M PGE₂ from 0–12 h. The results show increased phosphorylation of I- κ B as early as 1 h following treatment of the cells with PGE₂. The PGE₂-induced phosphorylation of I- κ B was maximal at 3 h and was still evident following 12 h of treatment. PGE₂ stimulation of the human EP₁ receptor can therefore activate NF- κ B transcriptional activity by a mechanism involving the phosphorylation of I- κ B.

Next, we examined the potential involvement of NF- κ B and CREB signalling in the PGE₂-stimulated up-regulation of Nurr1 by the EP₁ receptor. Figure 3A shows an immunoblot for the PGE₂-stimulated expression of Nurr1 in HEK-EP1 cells under control conditions or following pretreatment with the NF- κ B inhibitor, BAY 11-7082 or dominant negative CREB. It is evident that under control conditions, treatment of cells with 1 μ M PGE₂ for 3 h caused a robust up-regulation of Nurr1 expression, whereas following pretreatment with either BAY 11-7082 or dominant negative CREB, the PGE₂-stimulated up-regulation of Nurr1 was completely blocked.

A luciferase reporter gene under the control of a NBRE was further used to examine the role of NF- κ B and CREB on the PGE₂-stimulated up-regulation of Nurr1 by the EP₁ receptor. Figure 3B shows PGE₂-stimulated NBRE-luciferase reporter activity in HEK-EP1 cells under control conditions or following pretreatment with BAY 11-7082 or dominant negative CREB. It can be seen that under control conditions, treatment of the cells with 1 μ M PGE₂ produced a nine-fold induction of luciferase transcriptional activity, reflecting the activation of the NBRE following the PGE₂ mediated up-regulation of Nurr1. However, following pretreatment of the cells with the NF- κ B inhibitor, BAY 11-7082, the PGE₂ stimulation of




Figure 2

PGE₂-stimulated NF-κB responsive luciferase reporter gene activity (A) and time course of phosphorylation of I-κBα (B) in HEK cells stably transfected with the human EP₁ receptor (HEK-EP1). (A) HEK-EP1 cells or HEK cells stably transfected with empty vector (HEK-pCEP4) were transiently transfected with an NF-κB luciferase reporter plasmid as described in the methods section and ~18 h later, were treated either vehicle (veh) or 1 μM PGE₂ at 37°C. Luciferase activity was determined the next day. Data are the means ± SEM of triplicate measurements from a representative experiment that was repeated three times. ****P* < 0.001 compared with the corresponding vehicle treatment; one-way ANOVA, followed by Bonferroni post-test. (B) HEK-EP1 cells were treated with 1 μM PGE₂ for the indicated times at 37°C and lysates were prepared and subjected to immunoblot analysis with antibodies against either phospho-I-κBα (p-I-κBα) or vinculin. A representative immunoblot is shown from one of three independent experiments.

luciferase reporter activity was inhibited by ~50%; and following pretreatment with dominant negative CREB, the PGE₂ stimulation of luciferase activity was decreased by ~60%.

The CREB family of proteins are also transcription factors that produce their actions through binding to CREs in target genes (Mayr and Montminy, 2001). Classically, the transcriptional activity of CREB is induced after phosphorylation of Ser¹³³ by cAMP-dependent protein kinase (PKA). However, a number of other kinases may also phosphorylate Ser¹³³ leading to the activation of CREB. To further explore the role of CREB in EP₁ receptor signalling, we investigated the activation of CREB transcriptional activity and the PKA-dependent phosphorylation of CREB in HEK-EP1 cells treated with PGE₂. Figure 4A shows that the transcriptional activity of a CREB responsive luciferase reporter gene was stimulated nearly 20-fold in HEK-EP1 cells by PGE₂, whereas in control HEK cells, treatment with PGE₂ produced a two-fold increase that was not statistically significant.




Figure 3

The effects of the NF-κB inhibitor, BAY 11-7082, and dominant negative CREB (DN-CREB) on PGE₂-stimulated Nurr1 protein expression (A) and on PGE₂-stimulated Nurr1 responsive (NBRE) luciferase reporter gene activity (B) in HEK cells stably expressing the human EP₁ receptor. (A) HEK-EP1 cells were transiently transfected with DN-CREB ~18 h prior to the experiment or were pretreated the day of the experiment with either vehicle (control) or 10 μM BAY 11-7082 for 30 min at 37°C, followed by treatment with either vehicle (veh) or 1 μM PGE₂ for 3 h at 37°C. Lysates were prepared and subjected to immunoblot analysis using antibodies against either Nurr1 or vinculin. A representative immunoblot is shown from one of three independent experiments. (B) HEK-EP1 cells were transiently transfected either alone with a NBRE luciferase reporter plasmid or together with a plasmid encoding DN-CREB as described in the methods section and ~18 h later were pretreated with either vehicle (control) or 10 μM BAY 11-7082 for 30 min at 37°C, followed by treatment with either vehicle (veh) or 1 μM PGE₂. Luciferase activity was determined the next day. Data are the means ± SEM of quadruplicate measurements from a representative experiment that was repeated three times. ****P* < 0.001; one-way ANOVA, followed by Bonferroni post-test.

In Figure 4B, C and D, immunoblot analysis was used to examine the PGE₂-induced phosphorylation of CREB in HEK-EP1 cells under control conditions or following pretreatment with various signalling pathway inhibitors. As shown in Figure 4B, both CREB and its closely related family member, activating transcription factor-1 (ATF-1), were rapidly phosphorylated after treatment with 1 μM PGE₂. Figure 4C shows neither BIM, wortmannin, nor BAPTA/AM, which respectively inhibit PKC, PI3K and Ca²⁺ signalling, had little effect on the PGE₂ stimulated phosphorylation of either CREB or ATF-1 as compared with the controls. In contrast, Figure 4D




Figure 4

PGE₂-stimulated CREB responsive (CRE) luciferase reporter gene activity (A) and PGE₂-stimulated phosphorylation of CREB and ATF-1 either alone or following pretreatment with various signalling pathway inhibitors (B, C, D) in HEK cells stably transfected with the human EP₁ receptor (HEK-EP1). (A) HEK-EP1 cells or HEK cells stably transfected with empty vector (HEK-pCEP4) were transiently transfected with a CREB responsive (CRE) luciferase reporter plasmid and ~18 h later were treated either vehicle (veh) or 1 μ M PGE₂ at 37°C. Luciferase activity was determined the next day. Data are the means $\pm$ SEM of quadruplicate measurements from a representative experiment that was repeated three times. *** P < 0.001 compared with the corresponding vehicle treatment; one-way ANOVA, followed by Bonferroni post-test. (B) HEK-EP1 cells were treated with 1 μ M PGE₂ for indicated times at 37°C and lysates were prepared and subjected to immunoblot analysis with antibodies against either phospho-CREB/ATF-1 (p-CREB/p-ATF-1) or CREB. (C, D) HEK-EP1 cells were pretreated for 30 min 37°C with either vehicle (control), or 10 μ M of the PKC inhibitor, bisindolylmaleimide I (BIM), or 10 μ M of the PI3K inhibitor wortmannin (wort), or 10 μ M of the Ca²⁺ signalling inhibitor, BAPTA/AM, or 10 and 5 μ M of the PKA inhibitors, H89 and PKI, respectively. They were then treated with either vehicle (veh) or 1 μ M PGE₂ for 5 min at 37°C. Lysates were prepared and subjected to immunoblot analysis as in panel B. Shown are representative immunoblots that were repeated at least three times for each antibody and condition.

shows that pretreatment of HEK-EP1 cells with PKA inhibitors, H89 or PKI markedly reduced the PGE₂-stimulated phosphorylation of CREB and ATF-1. These results suggest that PKA is the primary kinase responsible for the PGE₂-stimulated phosphorylation and activation of CREB by the human EP₁ receptor.

Nurr1 up-regulation by the EP₁ receptor involves the activation of PKA but is independent of cAMP formation

As noted in the introduction, agonist stimulation of the EP₁ receptor leads to the activation of Ca²⁺ signalling, although it is not associated with a robust activation of inositol phosphates turnover, nor with any changes in intracellular cAMP formation. Nonetheless, our findings suggested a possible induction of cAMP formation given the PKA-dependent phosphorylation of CREB demonstrated previously in Figure 4. We therefore examined the formation of intracellular cAMP in HEK-EP1 cells in response to treatment with PGE₂, as well as the potential involvement of PKA in the up-regulation of Nurr1 expression. Using HEK cells stably expressing the cAMP-stimulatory EP₂ receptor (HEK-EP2) as a positive control, Figure 5A shows that 1 µM PGE₂ strongly stimulated intracellular cAMP formation in HEK-EP2 cells but had no effect on the formation of intracellular cAMP in either control HEK cells or HEK-EP1 cells.

The PKA inhibitors, H89 and PKI, were then used to examine the potential involvement of PKA in the PGE₂-mediated up-regulation of Nurr1 by the EP₁ receptor. The immunoblots shown in Figure 5B and C, respectively, show that pretreatment of HEK-EP1 cells with either H89 or PKI blocked the PGE₂-stimulated up-regulation of Nurr1 as compared with the controls. Using a Nurr1 responsive luciferase reporter gene, Figure 5D shows that pretreatment of HEK-EP1 cells with H89 also inhibited the PGE₂ stimulation of Nurr1 transcriptional activity by 50%.

The phosphorylation of Thr¹⁹⁷ in the catalytic subunit of PKA (PKAc) is associated with the activation of PKA (Steinberg *et al.*, 1993). Thus, using immunoblot analysis, we examined the potential phosphorylation of PKAc in HEK-EP1 cells after treatment with 1 µM PGE₂. Figure 5E shows that treatment of HEK-EP1 cells with 1 µM PGE₂ resulted in a time-dependent phosphorylation of PKAc that was maximal at 3 h. Together, these data indicate that the up-regulation of Nurr1 following PGE₂ stimulation of the human EP₁ receptor involves an activation of PKA that does not require the induction of intracellular cAMP formation.

Agonist stimulation of the EP₁ receptor results in the phosphorylation of the p65 subunit of NF-κB, which involves the activation of PKA

In addition to its association with the regulatory subunit of PKA, the catalytic subunit of PKA (PKAc) is known to exist in an inactive complex with I-κB and NF-κB (Zhong *et al.*, 1997; Gambaryan *et al.*, 2010). Following the phosphorylation of I-κB, this complex dissociates yielding active PKAc and NF-κB. Active PKAc can then phosphorylate the p65 subunit of NF-κB at Ser²⁷⁶, which increases the transcriptional activity of NF-κB (Zhong *et al.*, 1997). Consequently, we analysed the phosphorylation of the p65 subunit of

NF-κB in whole cell lysates from HEK-EP1 cells after treatment with PGE₂ as well as the potential role of PKAc in this process. In Figure 6A and B, immunoblot analysis was used to determine the phosphorylation of the p65 subunit of NF-κB under control conditions or following pretreatment with the PKA inhibitors H89 and PKI. Figure 6A shows that the p65 subunit of NF-κB was phosphorylated within 1 h following treatment of HEK-EP1 cells with 1 µM PGE₂ and was maintained for at least 6 h. Figure 6B shows that the PGE₂-stimulated phosphorylation of p65 in HEK-EP1 cells was almost completely blocked by pretreatment with either H89 or PKI. Using a NF-κB responsive luciferase reporter gene, Figure 6C shows that pretreatment of HEK-EP1 cells with H89 decreased PGE₂-stimulated NF-κB transcriptional activity by approximately 70%, compared with the control cells. Together, these data show that agonist stimulation of the human EP₁ receptor results in a PKA-dependent increase in the phosphorylation and transcriptional activity of NF-κB.

Up-regulation of Nurr1 by the EP₁ receptor involves PGE₂-mediated activation of RhoA

Stimulation of the PI3K and Rho signalling pathways are among the mechanisms known to induce the phosphorylation of I-κB and activation of NF-κB transcriptional activity (Perona *et al.*, 1997; Vallabhapurapu and Karin, 2009). We have previously shown that agonist stimulation of the human EP₁ receptor can up-regulate the expression of HIF-1α by a mechanism involving coupling to G_i and activation of a PI3K, Akt and mTOR signalling cascade (Ji *et al.*, 2010). It is therefore possible that the activation of NF-κB signalling that is necessary for the PGE₂-stimulated up-regulation of Nurr1 is through the EP₁ receptor-mediated activation of PI3K signalling. However, pretreatment of HEK-EP1 cells with the G_i inhibitor, Pertussis toxin, had no effect on the PGE₂-stimulated up-regulation of Nurr1, suggesting that the activation of NF-κB, which precedes the up-regulation of Nurr1, does not involve the activation of PI3K (data not shown). Furthermore, Figure 4C shows that the PI3K inhibitor, wortmannin, did not block the PGE₂-mediated phosphorylation of CREB, which is also required for the PGE₂-stimulated up-regulation of Nurr1 by the EP₁ receptor.

C3 exoenzyme, which is a potent inhibitor of RhoA, was then used to examine the potential role of Rho signalling in the up-regulation of Nurr1 by the EP₁ receptor. Figure 7A and B, respectively, show immunoblots for the PGE₂-stimulated expression of Nurr1 and phospho-I-κB following pretreatment of HEK-EP1 cells with C3 toxin. In Figure 7A, pretreatment of HEK-EP1 cells with C3 toxin completely blocked the PGE₂-stimulated up-regulation of Nurr1 as compared with control. Figure 7B shows that pretreatment of HEK-EP1 cells with C3 toxin also decreased the PGE₂-induced phosphorylation of I-κB. Together, these results suggest a mechanism for the PGE₂-stimulated up-regulation of Nurr1 that involves sequential activation of the EP₁ receptor, Rho, phosphorylation of I-κB, dissociation and activation of PKAc from the I-κB/NF-κB/PKAc complex, phosphorylation of NF-κB and CREB by PKAc and transcriptional up-regulation of Nurr1 through the combined actions of phospho-NF-κB and phospho-CREB.




Figure 5

PGE₂-stimulated cAMP formation (A); effects of the PKA inhibitors, H89 and PKI on PGE₂-stimulated Nurr1 protein expression (B, C) and on Nurr1-stimulated (NBRE) luciferase reporter gene activity (D); and PGE₂-stimulated phosphorylation of the catalytic subunit of PKA (E) in HEK cells stably transfected with the human EP₁ receptor (HEK-EP1). (A) HEK-EP1 cells, HEK cells stably transfected with empty vector (HEK-pCEP4), and HEK cells stably transfected with the cAMP stimulatory EP₂ receptor (HEK-EP2), were treated with either vehicle (veh) or 1 μ M PGE₂ at 37°C for 60 min and intracellular cAMP formation was measured. Data are the means $\pm$ SEM of duplicate measurements from a representative experiment that was repeated three times. *** P < 0.001 compared with the corresponding vehicle treatment; one-way ANOVA, followed by Bonferroni post-test. (B, C) HEK-EP1 cells were pretreated with vehicle (control) or 10 μ M H89 or 5 μ M PKI, for 30 min 37°C and were then treated with either vehicle (veh) or 1 μ M PGE₂ for 3 h. Lysates were prepared and subjected to immunoblot analysis using antibodies against either Nurr1, ERK 1/2 or vinculin. Shown are representative immunoblots that were repeated at least three times for each antibody and condition. (D) HEK-EP1 cells were transfected with a NBRE luciferase reporter plasmid and ~18 h later were pretreated for 30 min 37°C with either vehicle (control) or 10 μ M H89 followed by treatment with either vehicle (veh) or 1 μ M PGE₂. Luciferase activity was determined the next day. Data are the means $\pm$ SEM of quadruplicate measurements from a representative experiment that was repeated three times. *** P < 0.001; one-way ANOVA, followed by Bonferroni post-test. (E) HEK-EP1 cells were treated with 1 μ M PGE₂ for indicated times at 37°C and lysates were prepared and subjected to immunoblot analysis with antibodies against either the phosphorylated catalytic subunit of PKA (p-PKA) or vinculin. A representative immunoblot is shown from one of three independent experiments.

PGE₂ up-regulates Nurr1 protein and mRNA expression in SH-SY5Y neuroblastoma cells through activation of the EP₁ receptor

We have previously documented the expression of EP₁ receptor mRNA in SH-SY5Y human neuroblastoma cells (Ji *et al.*, 2010). Nurr1 is also expressed in these cells and has been

shown to be up-regulated by stimulation of the dopamine D₃ receptors (Pan *et al.*, 2005). We, therefore, decided to examine the possible up-regulation of Nurr1 by PGE₂ through the activation of endogenous EP₁ receptors in SH-SY5Y cells. Figure 8A shows an immunoblot for the PGE₂-stimulated expression of Nurr1 in SH-SY5Y cells either under control conditions or following pretreatment with the EP₁ receptor




Figure 6

Time course of the PGE₂-stimulated phosphorylation of the p65 subunit of NF-κB (A) and effects of the PKA inhibitors, H89 and PKI on the PGE₂-stimulated phosphorylation of p65 (B) and on PGE₂-stimulated NF-κB responsive luciferase reporter gene activity (C) in HEK cells stably transfected with the human EP₁ receptor (HEK-EP1). (A) HEK-EP1 cells were treated with 1 μM PGE₂ for indicated times at 37°C and whole cell lysates were prepared and subjected to immunoblot analysis with antibodies against either phospho-p65 or total p65. (B) HEK-EP1 cells were pretreated with vehicle (control) or 10 μM H89 or 5 μM PKI for 30 min 37°C and were then treated with either vehicle (veh) or 1 μM PGE₂ for 3 h. Lysates were prepared and subjected to immunoblot analysis as in panel A. Shown are representative immunoblots that were repeated at least three times for each antibody and condition. (C) HEK-EP1 cells were transiently transfected with a NF-κB luciferase reporter plasmid and ~18 h later were pretreated for 30 min 37°C with either vehicle (control) or 10 μM H89 followed by treatment with either vehicle (veh) or 1 μM PGE₂. Luciferase activity was determined the next day. Data are the means ± SEM of triplicate measurements from a representative experiment that was repeated three times. ****P* < 0.001; one-way ANOVA, followed by Bonferroni post-test.

antagonist SC-51322. The data show that the expression of Nurr1 increased at 3 h and 6 h after treatment with 1 μM PGE₂ and that this up-regulation of Nurr1 expression could be blocked by pretreatment with SC-51322. The PGE₂-stimulated expression of Nurr1 mRNA in SH-SY5Y cells was also examined by qPCR and the results are shown in Figure 8B. Nurr1 mRNA expression was strongly induced as early as 1 h after treatment with 1 μM PGE₂ and was maintained up to 6 h.

PGE₂ stimulation of the EP₁ receptor in SH-SY5Y neuroblastoma cells induces CREB/ATF-1 phosphorylation and




Figure 7

The effects of the Rho inhibitor, C3 toxin, on PGE₂-stimulated Nurr1 protein expression (A) and the phosphorylation of I-κBα (B) in HEK cells stably transfected with the human EP₁ receptor (HEK-EP1). (A, B) HEK-EP1 cells were pretreated with either vehicle (control) or 5 μM C3 toxin overnight and were then incubated with either vehicle (veh) or 1 μM PGE₂ for 3 h at 37°C. Lysates were prepared and subjected to immunoblot analysis with antibodies against either Nurr1, phospho-I-κBα (p-I-κBα) or vinculin. Representative immunoblots are shown that were repeated at least three times for each antibody and condition.

increases Nurr1 transcriptional activity that is dependent upon the activation of NF-κB and PKA. Figure 8C shows an immunoblot for the PGE₂-stimulated expression of phospho-CREB and phospho-ATF-1 in SH-SY5Y cells either under control conditions of following pretreatment with the EP₁ receptor antagonist, SC-51322. After 3 and 6 h of treatment with PGE₂, there was an up-regulation of the expression of phospho-CREB and phospho-ATF-1 that was decreased by pretreatment with SC-51322. A Nurr1 responsive (NBRE) luciferase reporter gene was used to examine PGE₂-stimulated Nurr1 transcriptional activity in SH-SY5Y cells either under control conditions or following pretreatment with various signalling pathway inhibitors, and the results are shown in Figure 8D. Under control conditions, incubation of SH-SY5Y cells with 1 μM PGE₂ resulted in a nearly eight-fold increase in Nurr1 transcriptional activity. This PGE₂-stimulated increase in Nurr1 transcriptional activity was decreased ~80% following pretreatment with the NF-κB inhibitor, BAY 11-7082, and it was completely blocked by pretreatment with the PKA inhibitor, H89. Pretreatment with the EP₁ receptor antagonist, SC-51322, also completely blocked the PGE₂-stimulated up-regulation of Nurr1 transcriptional activity in SH-SY5Y cells. Together, these data show that activation of endogenous EP₁ receptors in SH-SY5Y cells by PGE₂ can




Figure 8

PGE₂-stimulated Nurr1 protein expression (A) and mRNA expression (B); PGE₂-stimulated phosphorylation of CREB and ATF-1 (C); and PGE₂-stimulated Nurr1 responsive (NBRE) luciferase reporter gene activity (D) in SH-SY5Y neuroblastoma cells in the presence and absence of the EP₁ receptor antagonist, SC-51322 and various signalling pathway inhibitors. (A) SH-SY5Y cells were pretreated with either vehicle (control) or 1 μ M SC-51322 for 30 min at 37°C and were then incubated with 1 μ M PGE₂ for the indicated times. Lysates were prepared and subjected to immunoblot analysis using antibodies against Nurr1 or vinculin. (B) SH-SY5Y cells were incubated with 1 μ M PGE₂ at 37°C for the indicated times and then RNA was isolated and used for quantitative real-time PCR with primers specific for either Nurr1 or GAPDH as described in the methods section. Data were analysed by the comparative $\Delta\Delta$ Ct method, relative to the expression of GAPDH. Data are the means $\pm$ SEM ($n = 4$) of the pooled data from two independent experiments, each in duplicate. (C) SH-SY5Y cells were pretreated with either vehicle (control) or 1 μ M SC-51322 for 30 min at 37°C and were then incubated with 1 μ M PGE₂ for indicated times. Lysates were prepared and subjected to immunoblot analysis with antibodies against either phospho-CREB/ATF-1 (p-CREB/p-ATF-1) or CREB. (D) SH-SY5Y cells were transiently transfected with an NBRE luciferase reporter plasmid and ~18 h later were pretreated with vehicle (control) or 10 μ M of the NF- κ B inhibitor BAY 11-7082 (BAY) or 10 μ M of the PKA inhibitor H89 or 1 μ M SC-51322 (SC) for 30 min at 37°C, followed by treatment with either vehicle (veh) or 1 μ M PGE₂. Luciferase activity was determined the next day. Data are the means $\pm$ SEM of quadruplicate measurements from a representative experiment that was repeated three times. *** $P < 0.001$; * $P < 0.05$ compared with time 0 or with the corresponding vehicle control; one-way ANOVA, followed by Bonferroni post-test. Immunoblots are representative from one of at least three independent experiments.




Figure 9

Model for the signalling pathways activated by the human prostanoid EP₁ receptor. PGE₂ stimulation of the EP₁ receptor has typically been associated with the activation of Ca²⁺ signalling through coupling to G_q and the activation of phospholipase-Cβ (PLCβ). Recently, PGE₂ stimulation of the EP₁ receptor has been shown to result in coupling to G_i and activation of a PI3K, PKB (Akt) and mammalian target of rapamycin (mTOR) signalling cascade (Ji *et al.*, 2010). The present study shows that PGE₂ stimulation of the EP₁ receptor can up-regulate the expression of Nurr1 through the sequential activation of Rho, phosphorylation of I-κB, dissociation and activation of the catalytic subunit of PKA (PKAc) from an IκB/NF-κB/PKAc complex, followed by PKAc-dependent phosphorylation and activation of NF-κB and CREB.

up-regulate the expression of Nurr1 by a transcriptional mechanism that involves the activation of NF-κB and PKA.

Discussion

As depicted in Figure 9, the prostanoid EP₁ receptor has been classically thought to couple to G_{q/11} to activate Ca²⁺ signalling and smooth muscle contraction. While there is no doubt regarding the activation of Ca²⁺ signalling, it is unclear if this is mediated by conventional activation of phospholipase Cβ, as the stimulation of inositol phosphates formation by the EP₁ receptor is modest as compared with other receptors that are known to couple to G_{q/11} (see Sugimoto and Narumiya, 2007). We have recently shown that the human EP₁ receptor also couples to G_i to activate a PI3K, Akt and mTOR signalling cascade that results in the up-regulation of HIF-1α (Ji *et al.*, 2010). We now report that PGE₂ stimulation of the human EP₁ receptor can up-regulate the expression of the orphan nuclear receptor, Nurr1, both in HEK cells stably expressing the EP₁ receptor and in SH-SY5Y human neuroblastoma cells expressing endogenous EP₁ receptors. Figure 9 shows that the mechanism of this up-regulation involves the activation of Rho followed by a novel cAMP-independent activation of PKAc. Thus, PGE₂ stimulation of the EP₁ receptor activates Rho, leading to the phosphorylation of I-κB and subsequent dissociation and activation of PKAc from an IκB/NF-κB/PKAc complex. Activated PKAc then phosphorylates NF-κB and CREB, resulting in the transcriptional up-regulation of Nurr1 mRNA and protein expression, as well as increased Nurr1-

mediated transcriptional activity. It is generally recognized that receptors that couple to G_{q/11} frequently couple to G_{12/13}, which in turn are well known to activate Rho signalling pathways (Kurose, 2003; Juneja and Casey, 2009). It seems likely, therefore, that the activation of Rho by the EP₁ receptor involves coupling to G_{12/13}. In addition to the up-regulation of Nurr1, the activation of Rho, PKA, NF-κB and CREB are signalling properties that have not been previously ascribed to agonist stimulation of the EP₁ receptor.

The up-regulation of Nurr1 by PGE₂ was first described in colon cancer cells (Holla *et al.*, 2006) and later in rheumatoid arthritis synovial tissue (McEvoy *et al.*, 2002); however, neither study identified the nature of the specific EP receptor subtype mediating this response. Furthermore, although both studies suggested that this up-regulation involved the activation of cAMP/PKA, neither study measured PGE₂-stimulated cAMP formation so the actual role of cAMP was unclear. Nevertheless, Holla *et al.* (2006) clearly established a role for PKA by showing that the PKA inhibitor, H-89, completely blocked the PGE₂-stimulated up-regulation of Nurr1. Importantly, these authors also demonstrated that the anti-apoptotic effects of PGE₂ on colon cancer cells could be blocked with a dominant negative construct of Nurr1, suggesting that ability of PGE₂ to protect cells from undergoing apoptosis is achieved through the up-regulation of Nurr1.

The importance of NF-κB and CREB in the transcriptional up-regulation of Nurr1 in synovial tissue was clearly delineated by McEvoy *et al.*, (2002). They found that the up-regulation of Nurr1 by IL-1β and TNF-α involved the binding of NF-κB to a consensus site in the proximal pro-

moter of the *Nurr1* gene. Likewise, the up-regulation of *Nurr1* by PGE_2 required the binding of CREB to a CRE slightly downstream of the NF- κB binding site. In contrast to the present findings, however, the two sites appeared to function independently of one another; that is, activation of either site increased *Nurr1* transcriptional activity, and the activities were additive. We have observed that the up-regulation of *Nurr1* by PGE_2 in HEK cells requires the activation of both NF- κB and CREB, which can be provided entirely by agonist stimulation of the EP_1 receptor. McEvoy *et al.*, (2002) found that stimulation of intracellular cAMP formation by forskolin increased the expression of *Nurr1* via CREB activation; but their data also show that the effects of forskolin were markedly less than those produced by PGE_2 , suggesting the involvement of additional signalling pathways in the up-regulation of *Nurr1* by PGE_2 .

Activation of the thromboxane A_2 receptor (TP) has recently been shown to up-regulate the expression of *Nurr1* in human lung cancer cells (Li and Tai, 2009). This up-regulation of *Nurr1* was brought about through the activation of PKA and CREB, combined with activation of the PKC and MAPK/ERK pathways. Li and Tai (2009) also found that stimulation of intracellular cAMP formation with forskolin up-regulated the expression of *Nurr1*, but since they did not measure intracellular cAMP formation, it is not known if the TP receptor-mediated activation of PKA is cAMP-dependent or not. Li and Tai (2009), however, did provide evidence that NF- κB was not involved in the up-regulation of *Nurr1* by the TP receptor. These authors also found that PGE_2 stimulated the up-regulation of *Nurr1* in some lung cancer cell lines but not others. In responsive cell lines, the PGE_2 -stimulated up-regulation of *Nurr1* was blocked by the PKA inhibitor H-89, but in contrast to TP receptor activation, the up-regulation of *Nurr1* by PGE_2 was not affected by inhibition of the MAPK/ERK pathway. Because of the involvement of PKA, Li and Tai (2009) attributed the up-regulation of *Nurr1* by PGE_2 to possible activation of the cAMP stimulatory EP_2 and/or EP_4 receptors. Interestingly, however, the two lung cancer cell lines that did not respond to PGE_2 did not appear to express mRNA encoding the EP_1 receptor, whereas they did express mRNA encoding either the EP_2 or EP_4 receptors, suggesting that the up-regulation of *Nurr1* by PGE_2 in the responsive cell lines was mediated by activation of EP_1 receptors.

Pathophysiological involvement of the EP_1 receptor has been implicated in the development and/or progression of colon, lung, breast and skin cancer (Chell *et al.*, 2006; Fulton *et al.*, 2006). Our finding of the up-regulation of *Nurr1* by the EP_1 receptor provides a potential mechanism that is consistent with this role. Thus, *Nurr1* has been shown to have anti-apoptotic effects in colon cancer cells (Holla *et al.*, 2006), as well as in cervical carcinoma cells where it also increases anchorage-independent growth (Ke *et al.*, 2004). The anti-apoptotic effects of *Nurr1* appear to involve an interaction with p53 that inhibits its transcriptional activity and is associated with decreased expression of the pro-apoptotic protein, Bax (Zhang *et al.*, 2009). We have previously shown that PGE_2 stimulation of the human EP_1 receptor up-regulates the expression of HIF-1 α , a transcription factor that has also been associated with tumour angiogenesis and metastasis (Ji *et al.*, 2010). Thus, pathophysiological activation of the

EP_1 receptor could promote tumorigenesis by potentially up-regulating the expression of both *Nurr1* and HIF-1 α .

The ability of *Nurr1* to promote cell survival is perhaps best recognized in the CNS where the expression of *Nurr1* is essential for the development and maintenance of midbrain dopaminergic neurons (Zetterstrom *et al.*, 1997) and has been associated with neuroprotection (Volakakis *et al.*, 2010). For example, genetic ablation of *Nurr1* in the adult mouse brain resulted in a progressive loss of tyrosine hydroxylase activity and dopamine that is reminiscent of the changes seen in Parkinson's disease (Kadkhodaei *et al.*, 2009). Similarly, *Nurr1* expression in astrocytes and microglia has been shown to protect dopaminergic neurons from cell death by suppressing the production of pro-inflammatory neurotoxic mediators (Saijo *et al.*, 2009). It is puzzling, therefore, why activation of EP_1 receptors in the CNS is strongly associated with neurotoxicity (reviewed in the Introduction) when our present findings would suggest that the up-regulation of *Nurr1* by the EP_1 receptor would have neuroprotective effects in the brain.

In short, we do not have a good answer to this potential paradox except that EP_1 receptor activation *in vivo* may simply not up-regulate the expression of *Nurr1* in the brain. Another possibility is that activation of the EP_1 receptor in the brain may up-regulate the expression of the other NR4A family members (Nur77 and Nor-1) besides, or in addition to, the up-regulation of *Nurr1*. The up-regulation of Nur77 in particular has been shown to be strongly pro-apoptotic in a number of cells and tissues where it acts by a transcriptionally independent mechanism to convert Bcl-2 from an anti-apoptotic molecule into a pro-apoptotic one (Li *et al.*, 2000; Thompson and Winoto, 2008; Cheng *et al.*, 2011). Additionally, the up-regulation of *Nurr1* by PGE_2 is often accompanied by the simultaneous up-regulation of Nur77. For example, PGE_2 has been shown to up-regulate the expression of both *Nurr1* and Nur77 in synoviocytes (McEvoy *et al.*, 2002) and in chondrocytes (Mix *et al.*, 2007). In cementoblastic cells, PGE_2 was found to up-regulate the expression of Nur77 through specific activation of the EP_1 receptor (Moldovan *et al.*, 2009). It is also possible that the effect of the induced expression of *Nurr1* in brain cells is different from the constitutive expression of *Nurr1* that is required for the maintenance of dopaminergic neurons. Thus, it has been reported that ectopic over-expression of *Nurr1* increased apoptosis in SK-N-SH neuroblastoma cells exposed to the neurotoxin, 6-hydroxydopamine (Liu *et al.*, 2005).

In summary, we have found that activation of the human EP_1 receptor by PGE_2 leads to a cAMP-independent activation of PKA resulting in transcriptional up-regulation of *Nurr1* through the actions of CREB and NF- κB . This up-regulation of *Nurr1* may underlie the known tumorigenic potential of EP_1 receptors in cancer and inflammation. In the brain, activation of EP_1 receptors is known to mediate neurotoxicity; however, whether the potential up-regulation of *Nurr1* facilitates or offsets this neurotoxicity is presently unknown and would be interesting to address in future studies.

Acknowledgements

This work was supported in part by grants from the National Institutes of Health (NIH) (EY11291) and by Allergan Inc.

Portions of this work were also made possible by grants to the Arizona Cancer Center Genomics Facility Core (5P30 ES06694-14900209).

Conflict of interest

The authors state no conflict of interest.

References

- Ahmad AS, Saleem S, Ahmad M, Doré S (2006). Prostaglandin EP₁ receptor contributes to excitotoxicity and focal ischemic brain damage. *Toxicol Sci* 89: 265–270.
- Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. *Br J Pharmacol* 164 (Suppl. 1): S1–S324.
- Carrasco E, Casper D, Werner P (2007). PGE₂ receptor EP₁ renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE₂ neurotoxicity. *J Neurosci Res* 85: 3109–3117.
- Chell S, Kadi A, Williams AC, Paraskeva C (2006). Mediators of PGE₂ synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. *Biochim Biophys Acta* 1766: 104–119.
- Cheng Z, Völkers M, Din S, Avitabile D, Khan M, Gude N *et al.* (2011). Mitochondrial translocation of Nur77 mediates cardiomyocyte apoptosis. *Eur Heart J* 32: 2179–2188.
- Coleman RA, Smith WL, Narumiya S (1994). VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol Rev* 46: 205–229.
- Fujino H, Regan JW (2006). EP₄ prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G-protein. *Mol Pharmacol* 69: 13–18.
- Fujino H, West KA, Regan JW (2002). Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP₂ and EP₄ prostanoid receptors by prostaglandin E₂. *J Biol Chem* 277: 2614–2619.
- Fulton AM, Ma X, Kundu N (2006). Targeting prostaglandin E EP receptors to inhibit metastasis. *Cancer Res* 66: 9794–9797.
- Gambaryan S, Kobsar A, Rukoyatkina N, Herterich S, Geiger J, Smolenski A *et al.* (2010). Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NF- κ B-I κ B complex. *J Biol Chem* 285: 18352–18363.
- Han C, Michalopoulos GK, Wu T (2006). Prostaglandin E₂ receptor EP₁ transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. *J Cell Physiol* 207: 261–270.
- Hayden MS, Ghosh S (2008). Shared principles in NF- κ B signaling. *Cell* 132: 344–362.
- Holla VR, Mann JR, Shi Q, DuBois RN (2006). Prostaglandin E₂ regulates the nuclear receptor NR4A2 in colorectal cancer. *J Biol Chem* 281: 2676–2682.
- Huang GW, Yang LY, Lu WQ (2005). Expression of hypoxia-inducible factor 1 α and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. *World J Gastroenterol* 11: 1705–1708.
- Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW (2010). EP₁ prostanoid receptor coupling to G_{i/o} upregulates the expression of hypoxia-inducible factor-1 α through activation of a phosphoinositide-3 kinase signaling pathway. *Mol Pharmacol* 77: 1025–1036.
- Juneja J, Casey PJ (2009). Role of G12 proteins in oncogenesis and metastasis. *Br J Pharmacol* 158: 32–40.
- Kadkhodaei B, Ito T, Joodmardi E, Mattsson B, Rouillard C, Carta M *et al.* (2009). Nurrl is required for maintenance of maturing and adult midbrain dopamine neurons. *J Neurosci* 29: 15923–15932.
- Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA *et al.* (2006). Prostaglandin E₂ EP₁ receptors: downstream effectors of COX-2 neurotoxicity. *Nat Med* 12: 225–229.
- Ke N, Claassen G, Yu DH, Albers A, Fan W, Tan P *et al.* (2004). Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis. *Cancer Res* 64: 8208–8212.
- Kotani M, Tanaka I, Ogawa Y, Usui T, Tamura N, Mori K *et al.* (1997). Structural organization of the human prostaglandin EP₃ receptor subtype gene (PTGER3). *Genomics* 40: 425–434.
- Kurose H (2003). Galph12 and Galph13 as key regulatory mediator in signal transduction. *Life Sci* 74: 155–161.
- Li X, Tai HH (2009). Activation of thromboxane A₂ receptors induces orphan nuclear receptor Nurrl expression and stimulates cell proliferation in human lung cancer cells. *Carcinogenesis* 30: 1606–1613.
- Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD *et al.* (2000). Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. *Science* 289: 1159–1164.
- Liu Y, Zhao Y, Zhang H, Liw E, Xu Q (2005). The effects of overexpression of Nurrl on vulnerability of SK-N-SH cells to neurotoxin 6-OHDA. *Chin Pharmacological Bulletin* 21(10): 1171–1176.
- Mayr B, Montminy M (2001). Transcriptional regulation by the phosphorylation-dependent factor CREB. *Nat Rev Mol Cell Biol* 2: 599–609.
- McEvoy AN, Murphy EA, Ponnio T, Conneely OM, Bresnihan B, FitzGerald O *et al.* (2002). Activation of nuclear orphan receptor NURRL transcription by NF- κ B and cyclic adenosine 5'-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. *J Immunol* 168: 2979–2987.
- Mix KS, Attur MG, Al-Mussawir H, Abramson SB, Brinckerhoff CE, Murphy EP (2007). Transcriptional repression of matrix metalloproteinase gene expression by the orphan nuclear receptor NURRL in cartilage. *J Biol Chem* 282: 9492–9504.
- Moldovan SM, Nervina JM, Tetradis S, Camargo PM (2009). Regulation of Nur77 gene expression by prostanoids in cementoblastic cells. *Arch Oral Biol* 54: 412–419.
- Pan T, Xie W, Jankovic J, Le W (2005). Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. *Neurosci Lett* 377: 106–109.
- Pearen M, Muscat GEO (2010). Minireview: nuclear hormone receptor 4A signaling: implications for metabolic disease. *Mol Endocrinol* 24: 1891–1903.

- Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC (1997). Activation of the nuclear factor- κ B by Rho, CDC42, and Rac-1 proteins. *Genes Dev* 11: 463–475.
- Regan JW (2003). EP2 and EP4 prostanoid receptor signaling. *Life Sci* 74: 143–153.
- Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG *et al.* (2009). A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. *Cell* 137: 47–59.
- Shigeishi H, Higashikawa K, Hatano H, Okui G, Tanaka F, Tran TT *et al.* (2011). PGE₂ targets squamous cell carcinoma cell with the activated epidermal growth factor receptor family for survival against 5-fluorouracil through NR4A2 induction. *Cancer Lett* 307: 227–236.
- Steinberg RA, Cauthron RD, Symcox MM, Shuntoh H (1993). Autoactivation of catalytic (C alpha) subunit of cyclic AMP-dependent protein kinase by phosphorylation of threonine 197. *Mol Cell Biol* 13: 2332–2341.
- Sugimoto Y, Narumiya S (2007). Prostaglandin E receptors. *J Biol Chem* 282: 11613–11617.
- Thompson J, Winoto A (2008). During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain. *J Exp Med* 205: 1029–1036.
- Vallabhapurapu S, Karin M (2009). Regulation and function of NF- κ B transcription factors in the immune system. *Annu Rev Immunol* 27: 693–733.
- Vinukonda G, Csiszar A, Hu F, Dummula K, Pandey NK, Zia MT *et al.* (2010). Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition. *Brain* 133: 2264–2280.
- Volakakis N, Kadkhodaei B, Joodmardi E, Wallis K, Panman L, Silvaggi J *et al.* (2010). NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. *Proc Natl Acad Sci U S A* 107: 12317–12322.
- Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T (1997). Dopamine neuron agenesis in Nurr1-deficient mice. *Science* 276: 248–250.
- Zhang T, Wang P, Ren H, Fan J, Wang G (2009). NGFI-B nuclear receptor Nurr1 interacts with p53 and suppresses its transcriptional activity. *Mol Cancer Res* 7: 1408–1415.
- Zhao Y, Bruemmer D (2010). NR4A orphan nuclear receptors transcriptional regulators of gene expression in metabolism and vascular biology. *Arterioscler Thromb Vasc Biol* 30: 1535–1541.
- Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S (1997). The transcriptional activity of NF- κ B is regulated by the I κ B-associated PKAc subunit through a cyclic AMP-independent mechanism. *Cell* 89: 413–424.